{
  "id": 6274832,
  "title": "enGene Reports Third Quarter 2026 Financial Results and Provides Business Update",
  "url": "https://urgent.news/2026/09/08/engene-reports-third-quarter-2026-financial-results-and-provides",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T11:38:10.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/engene-reports-third-quarter-2026-financial-results-and-provides-business-update"
  },
  "original_language": "en",
  "account": null,
  "summary": "Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND’s pivotal cohort planned for 4Q 2026 Pre-Biologics License Application (BLA) meeting with the FDA on track for 4Q 2026 Initiation of BLA submission for detalimogene planned for 4Q 2026 Detalimogene plus surfactant […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}